European Journal of Pharmaceutical Sciences (2019)
Update date:2022-08-30
Topics:
Tunki, Lakshmi
Kulhari, Hitesh
Vadithe, Lakshma Nayak
Kuncha, Madhusudana
Bhargava, Suresh
Pooja, Deep
Sistla, Ramakrishna
Globally, one in six deaths is reported due to cancer suggesting the critical need for development of advanced treatment regimens. In this study, solid lipid nanoparticles (SLN) were prepared and appended with polyethylene glycol (PEGylated) galactose and a multikinase inhibitor sorafenib (SRFB) was used as chemotherapeutic drug, for treating hepatocellular carcinoma (HCC). The nanoparticles were evaluated for in-vitro and in-vivo performances to showcase the targeting efficiency and therapeutic benefits of the sorafenib loaded ligand conjugated nanoparticles (GAL-SSLN). When compared with SRFB or Sorafenib loaded SLN, GAL-SSLN showed superior cytotoxicity and apoptosis in HepG2 (human hepatocellular carcinoma cells). In addition, in-vivo pharmacokinetics and real time biodistribution studies in BALB/c mice showed that the surface conjugation of nanoparticles with galactose resulted in better pharmacokinetic performance and targeted delivery of the nanoparticles to liver. Results indicated that GAL-SSLN showed promising attributes in terms of targeting sorafenib to liver and therapeutic efficacy.
View MoreWeifang Ocean Trading Co., Ltd.
Contact:+86-536-2081155
Address:Room2606, Yuqing Building, 518#, Yuquan Road, High-tech Development Zone, Weifang City, Shandong Province, China
Chengdu D-Innovation Pharmaceutical Co., Ltd
Contact:86-28-85105536
Address:1001, B6, No.88 Keyuan South Road, Chengdu Hi-Tech Zone
website:http://www.angchenchem.com
Contact:+86-510-88302099 82327577
Address:Rm. 404/405, Floor 4th, No. 983 FengXiang Road, Wuxi, China
TIANJIN ZHONGXIN CHEMTECH CO.,LTD.
Contact:86-022-89880739
Address:10B, Pan China International Center, No. 931 YingKou Road, TangGu, Tianjin, China, 300451
website:http://www.amadischem.com
Contact:86-571-89925085
Address:Watts Cosine.No.166.Xiangmao Road.
Doi:10.1016/S0008-6215(98)00251-1
(1998)Doi:10.1039/c1jm14250j
(2012)Doi:10.1016/S1386-1425(99)00004-9
(1999)Doi:10.1021/jacs.0c08948
(2020)Doi:10.1149/1.3528273
(2011)Doi:10.1080/00397911003707139
(2011)